Illumina (NASDAQ:ILMN) Reaches New 12-Month High - Here's Why

Key Points

• Illumina shares hit a new 52-week high, trading as high as $156.09 and last changing hands near $157.01, up about 4.3% on the day. The move comes as the stock continues to trade well above its 50-day and 200-day moving averages.
• Recent analyst opinions were mixed but generally cautious: several firms raised price targets, while others maintained neutral or underweight views. Overall, MarketBeat shows a Hold consensus and an average price target of $137.75.
• Illumina’s latest earnings beat expectations, with Q1 EPS of $1.15 versus the $1.05 consensus and revenue of $1.09 billion topping estimates. The company also reiterated FY2026 guidance of 5.15 to 5.30 EPS.

Illumina, Inc. (NASDAQ:ILMN - Get Free Report)'s share price hit a new 52-week high on Thursday . The company traded as high as $156.09 and last traded at $157.0050, with a volume of 250999 shares. The stock had previously closed at $150.17.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Weiss Ratings cut shares of Illumina from a "hold (c)" rating to a "hold (c-)" rating in a research report on Wednesday, April 29th. Barclays upped their price target on shares of Illumina from $110.00 to $122.00 and gave the stock an "underweight" rating in a research report on Friday, May 1st. UBS Group reaffirmed a "neutral" rating and set a $135.00 price target on shares of Illumina in a research report on Friday, February 6th. JPMorgan Chase & Co. upped their price target on shares of Illumina from $120.00 to $125.00 and gave the stock a "neutral" rating in a research report on Friday, May 1st. Finally, Piper Sandler decreased their price target on shares of Illumina from $195.00 to $170.00 and set an "overweight" rating for the company in a research report on Monday, February 9th. Seven analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, Illumina currently has a consensus rating of "Hold" and an average price target of $137.75.

Illumina Stock Up 4.3%

The firm has a 50 day moving average price of $132.17 and a two-hundred day moving average price of $131.55. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $23.70 billion, a price-to-earnings ratio of 28.50, a P/E/G ratio of 2.40 and a beta of 1.42.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company's revenue was up 4.8% on a year-over-year basis. During the same period last year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current year.

Insider Activity

In other news, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares of the company's stock, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 225,067 shares of the stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the transaction, the director directly owned 3,604,441 shares in the company, valued at $524,626,387.55. The trade was a 5.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 330,160 shares of company stock worth $48,028,308 in the last ninety days. Corporate insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Illumina

Several large investors have recently modified their holdings of ILMN. Capital World Investors lifted its position in shares of Illumina by 20.0% during the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company's stock worth $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. WCM Investment Management LLC lifted its position in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after purchasing an additional 1,851,848 shares during the last quarter. Invesco Ltd. lifted its position in shares of Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company's stock worth $360,426,000 after purchasing an additional 1,352,731 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company's stock worth $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Finally, Morgan Stanley lifted its position in shares of Illumina by 66.0% during the fourth quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company's stock worth $331,710,000 after purchasing an additional 1,005,474 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.